Avtozma®
Rheumatoid arthritis
MarketedApproved
Key Facts
About Celltrion
Celltrion's mission is to promote patient health by making advanced biologics affordable and accessible globally. It has achieved this by evolving from a contract manufacturer into a vertically integrated powerhouse, becoming the world's leading biosimilar producer with a robust pipeline. Its core strategy leverages massive, FDA/EMA-certified manufacturing capacity, a direct global sales network, and a deep R&D pipeline spanning biosimilars and novel biologics to drive growth and secure long-term market leadership.
View full company profileTherapeutic Areas
Other Rheumatoid arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase II/III |
| ERNA-201 | Eterna Therapeutics | Preclinical |
| Tc99m Tilmanocept | Navidea Biopharmaceuticals | Phase 2/3 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| LFD-200 | Lifordi Immunotherapeutics | Phase 1 |
| MEV-N01 | Mesenbio | Pre-clinical |
| CIT-013 | Citryll | Phase 2a |
| Restem-L | Restem | Phase 2 |
| ASIT Platform | Ahead Therapeutics | Pre-clinical |
| AX-158 | Artax Biopharma | Phase 2 |